Appendix 2—table 32. Antihypertensive User Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users.
| All Antihypertensive Users by BP: Unmatched | All Antihypertensive Users by BP: Matched | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | BP Non-user | BP User | p-value | All | BP Non-user | BP User | p-value | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||
| All Patients | 1,786,001 | 100.0% | 1,579,388 | 88.4% | 206,613 | 11.6% | 408,792 | 100.0% | 204,396 | 50.0% | 204,396 | 50.0% | ||
| Age | ||||||||||||||
| ≤20 | 16,789 | 0.9% | 16,586 | 1.1% | 203 | 0.1% | <0.001 | 411 | 0.1% | 208 | 0.1% | 203 | 0.1% | 1.00 |
| 21-40 | 146,733 | 8.2% | 145,872 | 9.2% | 861 | 0.4% | 1,728 | 0.4% | 868 | 0.4% | 860 | 0.4% | ||
| 41-50 | 231,818 | 13.0% | 229,150 | 14.5% | 2,668 | 1.3% | 5,333 | 1.3% | 2,667 | 1.3% | 2,666 | 1.3% | ||
| 51-60 | 435,554 | 24.4% | 413,155 | 26.2% | 22,399 | 10.8% | 44,796 | 11.0% | 22,399 | 11.0% | 22,397 | 11.0% | ||
| 61-70 | 459,631 | 25.7% | 390,664 | 24.7% | 68,967 | 33.4% | 137,730 | 33.7% | 68,862 | 33.7% | 68,868 | 33.7% | ||
| 71-80 | 309,680 | 17.3% | 237,749 | 15.1% | 71,931 | 34.8% | 140,882 | 34.5% | 70,439 | 34.5% | 70,443 | 34.5% | ||
| ≥81 | 185,796 | 10.4% | 146,212 | 9.3% | 39,584 | 19.2% | 77,912 | 19.1% | 38,953 | 19.1% | 38,959 | 19.1% | ||
| Gender | ||||||||||||||
| Female | 1,079,897 | 60.5% | 894,472 | 56.6% | 185,425 | 89.7% | <0.001 | 366,424 | 89.6% | 183,212 | 89.6% | 183,212 | 89.6% | 1.00 |
| Male | 706,104 | 39.5% | 684,916 | 43.4% | 21,188 | 10.3% | 42,368 | 10.4% | 21,184 | 10.4% | 21,184 | 10.4% | ||
| Region | ||||||||||||||
| Midwest | 347,103 | 19.4% | 313,523 | 19.9% | 33,580 | 16.3% | <0.001 | 67,058 | 16.4% | 33,529 | 16.4% | 33,529 | 16.4% | 1.00 |
| Northeast | 498,566 | 27.9% | 444,828 | 28.2% | 53,738 | 26.0% | 107,150 | 26.2% | 53,575 | 26.2% | 53,575 | 26.2% | ||
| South | 669,285 | 37.5% | 595,410 | 37.7% | 73,875 | 35.8% | 146,890 | 35.9% | 73,445 | 35.9% | 73,445 | 35.9% | ||
| West | 271,047 | 15.2% | 225,627 | 14.3% | 45,420 | 22.0% | 87,694 | 21.5% | 43,847 | 21.5% | 43,847 | 21.5% | ||
| Insurance | ||||||||||||||
| Commercial | 847,410 | 47.4% | 787,519 | 49.9% | 59,891 | 29.0% | <0.001 | 119,737 | 29.3% | 59,863 | 29.3% | 59,874 | 29.3% | 1.00 |
| Dual | 46,693 | 2.6% | 37,153 | 2.4% | 9,540 | 4.6% | 17,884 | 4.4% | 8,945 | 4.4% | 8,939 | 4.4% | ||
| Medicaid | 406,725 | 22.8% | 369,893 | 23.4% | 36,832 | 17.8% | 70,769 | 17.3% | 35,387 | 17.3% | 35,382 | 17.3% | ||
| Medicare | 485,173 | 27.2% | 384,823 | 24.4% | 100,350 | 48.6% | 200,402 | 49.0% | 100,201 | 49.0% | 100,201 | 49.0% | ||
| PCP Visit 2019 | ||||||||||||||
| No | 718,249 | 40.2% | 633,042 | 40.1% | 85,207 | 41.2% | <0.001 | 168,255 | 41.2% | 84,128 | 41.2% | 84,127 | 41.2% | 1.00 |
| Yes | 1,067,752 | 59.8% | 946,346 | 59.9% | 121,406 | 58.8% | 240,537 | 58.8% | 120,268 | 58.8% | 120,269 | 58.8% | ||
| Continuous Outcomes | ||||||||||||||
| mean | SD | mean | SD | mean | SD | p-value | mean | SD | mean | SD | mean | SD | p-value | |
| CCI | 0.95 | 1.64 | 0.95 | 1.64 | 0.94 | 1.68 | 0.02 | 0.95 | 1.67 | 0.95 | 1.67 | 0.95 | 1.68 | 0.68 |
BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation.